GFS Advisors’s AbbVie ABBV Stock Holding History

GFS Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,698	Closed	-$388K	–	161
2025 Q4	$388K	Buy	+1,698	New	+$387K	0.05%	148
2021 Q3	–	Sell	-1,813	Closed	-$204K	–	172
2021 Q2	$204K	Buy	+1,813	New	+$204K	0.05%	145
2018 Q3	–	Sell	-2,501	Closed	-$232K	–	136
2018 Q2	$232K	Hold	2,501	–	–	0.05%	136
2018 Q1	$237K	Sell	2,501 -17	-0.7%	-$1.87K	0.05%	132
2017 Q4	$244K	Buy	+2,518	New	+$237K	0.05%	130
2017 Q3	–	Sell	-11,248	Closed	-$816K	–	141
2017 Q2	$816K	Sell	11,248 -3,950	-26%	-$266K	0.18%	92
2017 Q1	$990K	Buy	15,198 +1,780	+13%	+$112K	0.2%	82
2016 Q4	$840K	Hold	13,418	–	–	0.18%	90
2016 Q3	$846K	Buy	+13,418	New	+$869K	0.19%	85
2016 Q2	–	Sell	-13,336	Closed	-$762K	–	125
2016 Q1	$762K	Buy	13,336 +5,000	+60%	+$279K	0.2%	86
2015 Q4	$494K	Sell	8,336 -197	-2%	-$11.3K	0.15%	105
2015 Q3	$464K	Sell	8,533 -2	-0%	-$130	0.16%	104
2015 Q2	$573K	Sell	8,535 -214	-2%	-$14K	0.19%	94
2015 Q1	$512K	Buy	+8,749	New	+$529K	0.18%	97

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GFS Advisors's ABBV Position: Q1 2026 in Review

GFS Advisors sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,698 shares — an estimated $388K sold.

GFS Advisors first reported a position in ABBV in Q1 2015 and held it in 14 quarters. The position peaked at $990K in Q1 2017. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

GFS Advisors reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
GFS Advisors sold 1,698 AbbVie shares in Q1 2026, an estimated $388K.
GFS Advisors first reported a position in AbbVie in Q1 2015 and held it in 14 quarters.
GFS Advisors's AbbVie position peaked at $990K in Q1 2017.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on GFS Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.